Cleavage of human kininogen fragments at Met-Lys by human tissue kallikrein. 1994

J Sueiras-Diaz, and D M Jones, and D Ashworth, and J Horton, and D M Evans, and M Szelke
Ferring Research Institute, University of Southampton Research Centre, Chilworth, UK.

1. Tissue kallikrein (TK) cleaves low molecular weight kininogen (LK) at two sites to release kallidin: site I (between Arg389 and Ser390) is a typical cleavage point for a trypsin-like enzyme whereas site II (between Met379 and Lys380) is unusual and unique to TK. In order to learn more about the structural requirements and mechanism of cleavage at site II, we studied the hydrolysis by TK of several synthetic LK fragments varying in length between 4 and 22 residues and containing either site II only or both sites I and II. 2. Blocking site I cleavage in LK fragments by substituting DArg for LArg at position 389 or omitting site I from the sequence still allowed cleavage to proceed at site II. Replacement or deletion of selected amino acid residues in these fragments demonstrated that the presence of Arg381 was essential for site II cleavage to occur whereas Pro383, Phe385 and Ser386 could be replaced with Ala without affecting binding or cleavage by TK. Ki values towards TK were determined for all LK fragments in order to compare their binding affinities to the enzyme. Short peptides containing site II only exhibited high Ki values (> or = 100 microM) whereas longer fragments containing both sites I and II had Ki values of 2-7 microM. 3. In order to bring sites I and II into close proximity spatially and thus facilitating efficient cleavage in the enzyme-substrate complex, we prepared several cyclic analogs of the longer LK fragments.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007609 Kallidin A decapeptide bradykinin homolog cleaved from kininogen by kallikreins. It is a smooth-muscle stimulant and hypotensive agent that acts by vasodilatation. Lysyl Bradykinin,Kallidin Tetraacetate,Kallidin, (D)-Isomer,Lys-Bradykinin,Lysine Bradykinin,N2-L-Lysylbradykinin,Bradykinin, Lysine,Bradykinin, Lysyl,Lys Bradykinin,N2 L Lysylbradykinin,Tetraacetate, Kallidin
D007610 Kallikreins Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77). Kallikrein,Kininogenase,Callicrein,Dilminal,Kallidinogenase,Kalliginogenase,Kallikrein A,Kallikrein B',Kallikrein Light Chain,Kinin-Forming Enzyme,Padutin,alpha-Kallikrein,beta-Kallikrein,beta-Kallikrein B,Enzyme, Kinin-Forming,Kinin Forming Enzyme,Light Chain, Kallikrein,alpha Kallikrein,beta Kallikrein,beta Kallikrein B
D007704 Kininogens Endogenous peptides present in most body fluids. Certain enzymes convert them to active KININS which are involved in inflammation, blood clotting, complement reactions, etc. Kininogens belong to the cystatin superfamily. They are cysteine proteinase inhibitors. HIGH-MOLECULAR-WEIGHT KININOGEN; (HMWK); is split by plasma kallikrein to produce BRADYKININ. LOW-MOLECULAR-WEIGHT KININOGEN; (LMWK); is split by tissue kallikrein to produce KALLIDIN. Cystatins, Kininogen,Kininogen,Prekinins,Prokinins,T-Kininogen,Thiostatin,Kininogen Cystatins,T Kininogen
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006868 Hydrolysis The process of cleaving a chemical compound by the addition of a molecule of water.
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining

Related Publications

J Sueiras-Diaz, and D M Jones, and D Ashworth, and J Horton, and D M Evans, and M Szelke
January 1979, Advances in experimental medicine and biology,
J Sueiras-Diaz, and D M Jones, and D Ashworth, and J Horton, and D M Evans, and M Szelke
May 1996, Immunopharmacology,
J Sueiras-Diaz, and D M Jones, and D Ashworth, and J Horton, and D M Evans, and M Szelke
September 1978, Hoppe-Seyler's Zeitschrift fur physiologische Chemie,
J Sueiras-Diaz, and D M Jones, and D Ashworth, and J Horton, and D M Evans, and M Szelke
August 1981, Journal of biochemistry,
J Sueiras-Diaz, and D M Jones, and D Ashworth, and J Horton, and D M Evans, and M Szelke
November 1995, The Biochemical journal,
J Sueiras-Diaz, and D M Jones, and D Ashworth, and J Horton, and D M Evans, and M Szelke
July 1980, The Journal of biological chemistry,
J Sueiras-Diaz, and D M Jones, and D Ashworth, and J Horton, and D M Evans, and M Szelke
January 1992, Agents and actions. Supplements,
J Sueiras-Diaz, and D M Jones, and D Ashworth, and J Horton, and D M Evans, and M Szelke
October 1983, Analytical biochemistry,
J Sueiras-Diaz, and D M Jones, and D Ashworth, and J Horton, and D M Evans, and M Szelke
January 1988, Histochemistry,
J Sueiras-Diaz, and D M Jones, and D Ashworth, and J Horton, and D M Evans, and M Szelke
July 2010, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!